Osprey Pharmaceuticals Lands $11,000,000 Series A Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e5000d0f-9ee6-4678-a853-8767e8005cba&Preview=1
Date
9/3/2008
Company Name
Osprey Pharmaceuticals
Mailing Address
425 California Street San Francisco, CA 94104
Company Description
Osprey Pharmaceuticals USA, together with its Montreal, Canada partner, Osprey Pharmaceuticals, Ltd., is developing a series of novel fusion protein therapeutics which selectively target and neutralize activated leukocytes that are implicated in a variety of inflammatory and immune disorders.
Website
http://www.ospreypharma.com/
Transaction Type
Venture Equity
Transaction Amount
$11,000,000
Transaction Round
Series A
Proceeds Purposes
Proceeds will also be applied to the discovery and development of additional therapeutics that have emerged from the company’s proprietary platform for the discovery of therapeutic Leukocyte Population Modulators (LPMs). LPMs specifically target chemokine-activated leukocytes that drive and/or maintain a variety of inflammatory and autoimmune disorders.
M&A Terms
Venture Investor
Burrill & Company
Venture Investor
Novo A/S
Venture Investor
BDC Venture Capital
Venture Investor
GeneChem
Venture Investor
Western Technology Investment